Cardiac Cell Therapy: Boosting Mesenchymal Stem Cells Effects

Stem Cell Reviews and Reports

Volumn 9, Issue 3, 2013, Pages 266-280

  Samper, E ^a   Diez Juan, A ^a   Montero, J A ^a   Sepulveda P ^a  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

Adult stem cells; Cardiac regeneration; Cell therapy; Genetic engineering; Mesenchymal stem cells; Myocardial infarction

Indexed keywords

BIOLOGICAL THERAPY; CELL DIFFERENTIATION; CYTOLOGY; GENETIC ENGINEERING; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PARACRINE SIGNALING; REGENERATION; REVIEW;

CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; GENETIC ENGINEERING; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION; REGENERATION;

EID: 84878998858     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-012-9353-z     Document Type: Review

References (155)

1. Mackay, J., & Mensah, G. (2004). Atlas of heart disease and stroke. World Health Organization.
2. Andersen, H. R., Nielsen, T. T., Rasmussen, K., et al. (2003). A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. The New England Journal of Medicine, 349(8), 733-742.
3. Costanzo, M. R., Augustine, S., Bourge, R., et al. (1995). Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation, 92(12), 3593-3612.
4. Kajstura, J., Cheng, W., Reiss, K., et al. (1996). Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Laboratory Investigation, 74(1), 86-107.
5. Sun, Y., Zhang, J. Q., Zhang, J., & Lamparter, S. (2000). Cardiac remodeling by fibrous tissue after infarction in rats. The Journal of Laboratory and Clinical Medicine, 135(4), 316-323.
6. Sutton, M. G., & Sharpe, N. (2000). Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation, 101(25), 2981-2988.
7. Segers, V. F., & Lee, R. T. (2008). Stem-cell therapy for cardiac disease. Nature, 451(7181), 937-942.
8. Tongers, J., Losordo, D. W., & Landmesser, U. (2011). Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. European Heart Journal, 32(10), 1197-1206.
9. Janssens, S. (2010). Stem cells in the treatment of heart disease. Annual Review of Medicine, 61, 287-300.
10. Arminan, A., Gandia, C., Garcia-Verdugo, J. M., et al. (2010). Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction. Journal of the American College of Cardiology, 55(20), 2244-2253.
11. Martinez, E. C., & Kofidis, T. (2011). Adult stem cells for cardiac tissue engineering. Journal of Molecular and Cellular Cardiology, 50(2), 312-319.
12. Herrmann, J. L., Abarbanell, A. M., Weil, B. R., et al. (2011). Optimizing stem cell function for the treatment of ischemic heart disease. Journal of Surgical Research, 166(1), 138-145.
13. Haider, H., & Ashraf, M. (2010). Preconditioning and stem cell survival. Journal of Cardiovascular Translational Research, 3(2), 89-102.
14. Menasche, P. (2011). Cardiac cell therapy: lessons from clinical trials. Journal of Molecular and Cellular Cardiology, 50(2), 258-265.
15. Rosenzweig, A. (2006). Cardiac cell therapy-mixed results from mixed cells. The New England Journal of Medicine, 355(12), 1274-1277.
16. Passier, R., van Laake, L. W., & Mummery, C. L. (2008). Stem-cell-based therapy and lessons from the heart. Nature, 453(7193), 322-329.
17. Fouts, K., Fernandes, B., Mal, N., Liu, J., & Laurita, K. R. (2006). Electrophysiological consequence of skeletal myoblast transplantation in normal and infarcted canine myocardium. Heart Rhythm, 3(4), 452-461.
18. Hagege, A. A., Marolleau, J. P., Vilquin, J. T., et al. (2006). Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation, 114(1 Suppl), I108-I113.
19. Fernandes, S., Amirault, J. C., Lande, G., et al. (2006). Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias. Cardiovascular Research, 69(2), 348-358.
20. Jeong, J. O., Han, J. W., Kim, J. M., et al. (2011). Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circulation Research, 108(11), 1340-1347.
21. Hatzistergos, K. E., Blum, A., Ince, T., Grichnik, J. M., & Hare, J. M. (2011). What is the oncologic risk of stem cell treatment for heart disease? Circulation Research, 108(11), 1300-1303.
22. Wollert, K. C., & Drexler, H. (2010). Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nature Reviews Cardiology, 7(4), 204-215.
23. Giordano, A., Galderisi, U., & Marino, I. R. (2007). From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. Journal of Cellular Physiology, 211(1), 27-35.
24. Hare, J. M., Traverse, J. H., Henry, T. D., et al. (2009). A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology, 54(24), 2277-2286.
25. Trachtenberg, B., Velazquez, D. L., Williams, A. R., et al. (2011). Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. American Heart Journal, 161(3), 487-493.
26. Williams, A. R., Trachtenberg, B., Velazquez, D. L., et al. (2011). Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circulation Research, 108(7), 792-796.
27. Friedenstein, A. J., Deriglasova, U. F., Kulagina, N. N., et al. (1974). Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Experimental Hematology, 2(2), 83-92.
28. Pittenger, M. F., Mackay, A. M., Beck, S. C., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411), 143-147.
29. Pereira, R. F., Halford, K. W., O'Hara, M. D., et al. (1995). Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proceedings of the National Academy of Sciences of the United States of America, 92(11), 4857-4861.
30. Sekiya, I., Vuoristo, J. T., Larson, B. L., & Prockop, D. J. (2002). In vitro cartilage formation by human adult stem cells from bone marrow stroma defines the sequence of cellular and molecular events during chondrogenesis. Proceedings of the National Academy of Sciences of the United States of America, 99(7), 4397-4402.
31. Prockop, D. J. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276(5309), 71-74.
32. Liechty, K. W., MacKenzie, T. C., Shaaban, A. F., et al. (2000). Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nature Medicine, 6(11), 1282-1286.
33. Sakaguchi, Y., Sekiya, I., Yagishita, K., & Muneta, T. (2005). Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis and Rheumatism, 52(8), 2521-2529.
34. Luria, E. A., Panasyuk, A. F., & Friedenstein, A. Y. (1971). Fibroblast colony formation from monolayer cultures of blood cells. Transfusion, 11(6), 345-349.
35. Kuznetsov, S. A., Mankani, M. H., Gronthos, S., Satomura, K., Bianco, P., & Robey, P. G. (2001). Circulating skeletal stem cells. The Journal of Cell Biology, 153(5), 1133-1140.
36. Zuk, P. A., Zhu, M., Mizuno, H., et al. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Engineering, 7(2), 211-228.
37. Toma, J. G., Akhavan, M., Fernandes, K. J., et al. (2001). Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nature Cell Biology, 3(9), 778-784.
38. Gronthos, S., Mankani, M., Brahim, J., Robey, P. G., & Shi, S. (2000). Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 97(25), 13625-13630.
39. Najimi, M., Khuu, D. N., Lysy, P. A., et al. (2007). Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplantation, 16(7), 717-728.
40. De Bari, C., Dell'Accio, F., Tylzanowski, P., & Luyten, F. P. (2001). Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis and Rheumatism, 44(8), 1928-1942.
41. Williams, J. T., Southerland, S. S., Souza, J., Calcutt, A. F., & Cartledge, R. G. (1999). Cells isolated from adult human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. American Surgeon, 65(1), 22-26.
42. Lama, V. N., Smith, L., Badri, L., et al. (2007). Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. The Journal of Clinical Investigation, 117(4), 989-996.
43. Erices, A., Conget, P., & Minguell, J. J. (2000). Mesenchymal progenitor cells in human umbilical cord blood. British Journal of Haematology, 109(1), 235-242.
44. In 't Anker, P. S., Scherjon, S. A., Kleijburg-van der Keur, C., et al. (2003). Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood, 102(4), 1548-1549.
45. In't Anker, P. S., Scherjon, S. A., Kleijburg-van der Keur, C., et al. (2004). Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells, 22(7), 1338-1345.
46. Hass, R., Kasper, C., Bohm, S., & Jacobs, R. (2011). Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Communication and Signaling, 9, 12.
47. Garcia-Castro, J., Trigueros, C., Madrenas, J., Perez-Simon, J. A., Rodriguez, R., & Menendez, P. (2008). Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. Journal of Cellular and Molecular Medicine, 12(6B), 2552-2565.
48. Wagner, W., Wein, F., Seckinger, A., et al. (2005). Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Experimental Hematology, 33(11), 1402-1416.
49. Simonsen, J. L., Rosada, C., Serakinci, N., et al. (2002). Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nature Biotechnology, 20(6), 592-596.
50. Asumda, F. Z., & Chase, P. B. (2011). Age-related changes in rat bone-marrow mesenchymal stem cell plasticity. BMC Cell Biology, 12, 44.
51. Ryan, J. M., Barry, F. P., Murphy, J. M., & Mahon, B. P. (2005). Mesenchymal stem cells avoid allogeneic rejection. Journal of Inflammation (London), 2, 8.
52. Beyth, S., Borovsky, Z., Mevorach, D., et al. (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood, 105(5), 2214-2219.
53. Rasmusson, I. (2006). Immune modulation by mesenchymal stem cells. Experimental Cell Research, 312(12), 2169-2179.
54. Jones, B. J., & McTaggart, S. J. (2008). Immunosuppression by mesenchymal stromal cells: from culture to clinic. Experimental Hematology, 36(6), 733-741.
55. Eliopoulos, N., Stagg, J., Lejeune, L., Pommey, S., & Galipeau, J. (2005). Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood, 106(13), 4057-4065.
56. Nauta, A. J., Westerhuis, G., Kruisselbrink, A. B., Lurvink, E. G., Willemze, R., & Fibbe, W. E. (2006). Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood, 108(6), 2114-2120.
57. Mirotsou, M., Jayawardena, T. M., Schmeckpeper, J., Gnecchi, M., & Dzau, V. J. (2011). Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. Journal of Molecular and Cellular Cardiology, 50(2), 280-289.
58. Wen, Z., Zheng, S., Zhou, C., Wang, J., & Wang, T. (2011). Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. Journal of Cellular and Molecular Medicine, 15(5), 1032-1043.
59. Chen, S., Liu, Z., Tian, N., et al. (2006). Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. The Journal of Invasive Cardiology, 18(11), 552-556.
60. Frangogiannis, N. G., Smith, C. W., & Entman, M. L. (2002). The inflammatory response in myocardial infarction. Cardiovascular Research, 53(1), 31-47.
61. Bonvini, R. F., Hendiri, T., & Camenzind, E. (2005). Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target? European Heart Journal Supplements, 7(suppl I), I27-I36.
62. Arslan, F., de Kleijn, D. P., & Pasterkamp, G. (2011). Innate immune signaling in cardiac ischemia. Nature Reviews Cardiology, 8(5), 292-300.
63. Nian, M., Lee, P., Khaper, N., & Liu, P. (2004). Inflammatory cytokines and postmyocardial infarction remodeling. Circulation Research, 94(12), 1543-1553.
64. Nah, D. Y., & Rhee, M. Y. (2009). The inflammatory response and cardiac repair after myocardial infarction. Korean Circulation Journal, 39(10), 393-398.
65. Kollar, K., Cook, M. M., Atkinson, K., & Brooke, G. (2009). Molecular mechanisms involved in mesenchymal stem cell migration to the site of acute myocardial infarction. International Journal of Cell Biology, p. 904682.
66. Neuss, S., Becher, E., Woltje, M., Tietze, L., & Jahnen-Dechent, W. (2004). Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells, 22(3), 405-414.
67. Kim, Y. S., Park, H. J., Hong, M. H., et al. (2009). TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. Frontiers in Bioscience, 14, 2845-2856.
68. Ponte, A. L., Marais, E., Gallay, N., et al. (2007). The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells, 25(7), 1737-1745.
69. Majumdar, M. K., Keane-Moore, M., Buyaner, D., et al. (2003). Characterization and functionality of cell surface molecules on human mesenchymal stem cells. Journal of Biomedical Science, 10(2), 228-241.
70. Thankamony, S. P., & Sackstein, R. (2011). Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cells. Proceedings of the National Academy of Sciences of the United States of America, 108(6), 2258-2263.
71. Steingen, C., Brenig, F., Baumgartner, L., Schmidt, J., Schmidt, A., & Bloch, W. (2008). Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. Journal of Molecular and Cellular Cardiology, 44(6), 1072-1084.
72. Segers, V. F., van Riet, I., Andries, L. J., et al. (2006). Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. American Journal of Physiology-Heart and Circulatory Physiology, 290(4), H1370-H1377.
73. Toma, C., Pittenger, M. F., Cahill, K. S., Byrne, B. J., & Kessler, P. D. (2002). Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation, 105(1), 93-98.
74. Grinnemo, K. H., Mansson, A., Dellgren, G., et al. (2004). Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. The Journal of Thoracic and Cardiovascular Surgery, 127(5), 1293-1300.
75. Terrovitis, J., Stuber, M., Youssef, A., et al. (2008). Magnetic resonance imaging overestimates ferumoxide-labeled stem cell survival after transplantation in the heart. Circulation, 117(12), 1555-1562.
76. Quevedo, H. C., Hatzistergos, K. E., Oskouei, B. N., et al. (2009). Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proceedings of the National Academy of Sciences of the United States of America, 106(33), 14022-14027.
77. Hatzistergos, K. E., Quevedo, H., Oskouei, B. N., et al. (2010). Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circulation Research, 107(7), 913-922.
78. Muller-Ehmsen, J., Krausgrill, B., Burst, V., et al. (2006). Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction. Journal of Molecular and Cellular Cardiology, 41(5), 876-884.
79. Freyman, T., Polin, G., Osman, H., et al. (2006). A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. European Heart Journal, 27(9), 1114-1122.
80. Serda, R. E., Gu, J., Bhavane, R. C., et al. (2009). The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials, 30(13), 2440-2448.
81. Laflamme, M. A., Chen, K. Y., Naumova, A. V., et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nature Biotechnology, 25(9), 1015-1024.
82. Godier-Furnemont, A. F., Martens, T. P., Koeckert, M. S., et al. (2011). Composite scaffold provides a cell delivery platform for cardiovascular repair. Proceedings of the National Academy of Sciences of the United States of America, 108(19), 7974-7979.
83. Trouche, E., Girod Fullana, S., Mias, C., et al. (2010). Evaluation of alginate microspheres for mesenchymal stem cell engraftment on solid organ. Cell Transplantation, 19(12), 1623-1633.
84. Shake, J. G., Gruber, P. J., Baumgartner, W. A., et al. (2002). Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. The Annals of Thoracic Surgery, 73(6), 1919-1925. discussion 1926.
85. Jiang, W., Ma, A., Wang, T., et al. (2006). Homing and differentiation of mesenchymal stem cells delivered intravenously to ischemic myocardium in vivo: a time-series study. Pflügers Archiv, 453(1), 43-52.
86. Noiseux, N., Gnecchi, M., Lopez-Ilasaca, M., et al. (2006). Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Molecular Therapy, 14(6), 840-850.
87. Arminan, A., Gandia, C., Bartual, M., et al. (2009). Cardiac differentiation is driven by NKX2. 5 and GATA4 nuclear translocation in tissue-specific mesenchymal stem cells. Stem Cells and Development, 18(6), 907-918.
88. Tang, Y. L., Zhao, Q., Qin, X., et al. (2005). Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. The Annals of Thoracic Surgery, 80(1), 229-236. discussion 236-7.
89. Gnecchi, M., He, H., Noiseux, N., et al. (2006). Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. The FASEB Journal, 20(6), 661-669.
90. Gnecchi, M., Zhang, Z., Ni, A., & Dzau, V. J. (2008). Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Research, 103(11), 1204-1219.
91. Uemura, R., Xu, M., Ahmad, N., & Ashraf, M. (2006). Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circulation Research, 98(11), 1414-1421.
92. Haynesworth, S. E., Baber, M. A., & Caplan, A. I. (1996). Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. Journal of Cellular Physiology, 166(3), 585-592.
93. Iso, Y., Spees, J. L., Serrano, C., et al. (2007). Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochemical and Biophysical Research Communications, 354(3), 700-706.
94. Prockop, D. J. (2007). "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clinical Pharmacology and Therapeutics, 82(3), 241-243.
95. Tang, J. M., Wang, J. N., Zhang, L., et al. (2011). VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovascular Research.
96. Nguyen, B. K., Maltais, S., Perrault, L. P., et al. (2010). Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. Journal of Cardiovascular Translational Research, 3(5), 547-558.
97. Timmers, L., Lim, S. K., Hoefer, I. E., et al. (2011). Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Research, 6(3), 206-214.
98. Zisa, D., Shabbir, A., Suzuki, G., & Lee, T. (2009). Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair. Biochemical and Biophysical Research Communications, 390(3), 834-838.
99. Huang, J., Zhang, Z., Guo, J., et al. (2010). Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circulation Research, 106(11), 1753-1762.
100. Zhang, D., Fan, G. C., Zhou, X., et al. (2008). Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. Journal of Molecular and Cellular Cardiology, 44(2), 281-292.
101. Zhang, M., Mal, N., Kiedrowski, M., et al. (2007). SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. The FASEB Journal, 21(12), 3197-3207.
102. Tang, J., Wang, J., Guo, L., et al. (2010). Mesenchymal stem cells modified with stromal cell-derived factor 1 alpha improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction. Molecules and Cells, 29(1), 9-19.
103. Duan, H. F., Wu, C. T., Wu, D. L., et al. (2003). Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Molecular Therapy, 8(3), 467-474.
104. Haider, H., Jiang, S., Idris, N. M., & Ashraf, M. (2008). IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circulation Research, 103(11), 1300-1308.
105. Liu, X. H., Bai, C. G., Xu, Z. Y., et al. (2008). Therapeutic potential of angiogenin modified mesenchymal stem cells: angiogenin improves mesenchymal stem cells survival under hypoxia and enhances vasculogenesis in myocardial infarction. Microvascular Research, 76(1), 23-30.
106. Gao, F., He, T., Wang, H., et al. (2007). A promising strategy for the treatment of ischemic heart disease: mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Canadian Journal of Cardiology, 23(11), 891-898.
107. Cho, J., Zhai, P., Maejima, Y., & Sadoshima, J. (2011). Myocardial injection with GSK-3beta-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circulation Research, 108(4), 478-489.
108. Grauss, R. W., van Tuyn, J., Steendijk, P., et al. (2008). Forced myocardin expression enhances the therapeutic effect of human mesenchymal stem cells after transplantation in ischemic mouse hearts. Stem Cells, 26(4), 1083-1093.
109. Alfaro, M. P., Vincent, A., Saraswati, S., et al. (2010). sFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. Journal of Biological Chemistry, 285(46), 35645-35653.
110. Kobayashi, K., Luo, M., Zhang, Y., et al. (2009). Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nature Cell Biology, 11(1), 46-55.
111. Alfaro, M. P., Pagni, M., Vincent, A., et al. (2008). The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proceedings of the National Academy of Sciences of the United States of America, 105(47), 18366-18371.
112. Mangi, A. A., Noiseux, N., Kong, D., et al. (2003). Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nature Medicine, 9(9), 1195-1201.
113. Jiang, S., Haider, H., Idris, N. M., Salim, A., & Ashraf, M. (2006). Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circulation Research, 99(7), 776-784.
114. Shujia, J., Haider, H. K., Idris, N. M., Lu, G., & Ashraf, M. (2008). Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovascular Research, 77(3), 525-533.
115. Tang, Y. L., Tang, Y., Zhang, Y. C., Qian, K., Shen, L., & Phillips, M. I. (2005). Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. Journal of the American College of Cardiology, 46(7), 1339-1350.
116. Tsubokawa, T., Yagi, K., Nakanishi, C., et al. (2010). Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia. American Journal of Physiology - Heart and Circulatory Physiology, 298(5), H1320-H1329.
117. Zeng, B., Lin, G., Ren, X., Zhang, Y., & Chen, H. (2010). Over-expression of HO-1 on mesenchymal stem cells promotes angiogenesis and improves myocardial function in infarcted myocardium. Journal of Biomedical Science, 17, 80.
118. Jiang, Y. B., Zhang, X. L., Tang, Y. L., et al. (2011). Effects of heme oxygenase-1 gene modulated mesenchymal stem cells on vasculogenesis in ischemic swine hearts. Chinese Medical Journal, 124(3), 401-407.
119. Shu, T., Zeng, B., Ren, X., & Li, Y. (2010). HO-1 modified mesenchymal stem cells modulate MMPs/TIMPs system and adverse remodeling in infarcted myocardium. Tissue & Cell, 42(4), 217-222.
120. Lim, S. Y., Kim, Y. S., Ahn, Y., et al. (2006). The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. Cardiovascular Research, 70(3), 530-542.
121. Yu, Y. S., Shen, Z. Y., Ye, W. X., et al. (2010). AKT-modified autologous intracoronary mesenchymal stem cells prevent remodeling and repair in swine infarcted myocardium. Chinese Medical Journal, 123(13), 1702-1708.
122. Wang, X., Zhao, T., Huang, W., et al. (2009). Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells, 27(12), 3021-3031.
123. Eun, L. Y., Song, B. W., Cha, M. J., et al. (2010). Overexpression of phosphoinositide-3-kinase class II alpha enhances mesenchymal stem cell survival in infarcted myocardium. Biochemical and Biophysical Research Communications, 402(2), 272-279.
124. Li, W., Ma, N., Ong, L. L., et al. (2007). Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells, 25(8), 2118-2127.
125. Wang, D., Shen, W., Zhang, F., Chen, M., Chen, H., & Cao, K. (2010). Connexin43 promotes survival of mesenchymal stem cells in ischaemic heart. Cell Biology International, 34(4), 415-423.
126. Guo, Y., He, J., Wu, J., et al. (2008). Locally overexpressing hepatocyte growth factor prevents post-ischemic heart failure by inhibition of apoptosis via calcineurin-mediated pathway and angiogenesis. Archives of Medical Research, 39(2), 179-188.
127. Deuse, T., Peter, C., Fedak, P. W., et al. (2009). Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation, 120(11 Suppl), S247-S254.
128. Yang, J., Zhou, W., Zheng, W., et al. (2007). Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology, 107(1), 17-29.
129. Kim, S. H., Moon, H. H., Kim, H. A., Hwang, K. C., Lee, M., & Choi, D. (2011). Hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells prevent myocardial ischemic injury. Molecular Therapy, 19(4), 741-750.
130. Chen, J. J., & Zhou, S. H. (2011). Mesenchymal stem cells overexpressing MiR-126 enhance ischemic angiogenesis via the AKT/ERK-related pathway. Cardiology Journal. 18(X), 1-X.
131. Song, S. W., Chang, W., Song, B. W., et al. (2009). Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium. Stem Cells, 27(6), 1358-1365.
132. Song, H., Chang, W., Lim, S., et al. (2007). Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived mesenchymal stem cells. Stem Cells, 25(6), 1431-1438.
133. Shibuya, M. (2001). Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Structure and Function, 26(1), 25-35.
134. Cross, M. J., & Claesson-Welsh, L. (2001). FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends in Pharmacological Sciences, 22(4), 201-207.
135. Galzie, Z., Kinsella, A. R., & Smith, J. A. (1997). Fibroblast growth factors and their receptors. Biochemical Cell Biology, 75(6), 669-685.
136. Le Roith, D. (1997). Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. New England Journal of Medicine, 336(9), 633-640.
137. Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A., & Springer, T. A. (1996). A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). The Journal of Experimental Medicine, 184(3), 1101-1109.
138. Dennler, S., Goumans, M. J., & ten Dijke, P. (2002). Transforming growth factor beta signal transduction. Journal of Leukocyte Biology, 71(5), 731-740.
139. Massague, J. (1998). TGF-beta signal transduction. Annual Review of Biochemistry, 67, 753-791.
140. van Snick, J. (1990). Interleukin-6: an overview. Annual Review of Immunology, 8, 253-278.
141. Zarnegar, R., & Michalopoulos, G. K. (1995). The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. The Journal of Cell Biology, 129(5), 1177-1180.
142. Tallquist, M., & Kazlauskas, A. (2004). PDGF signaling in cells and mice. Cytokine & Growth Factor Reviews, 15(4), 205-213.
143. Koblizek, T. I., Weiss, C., Yancopoulos, G. D., Deutsch, U., & Risau, W. (1998). Angiopoietin-1 induces sprouting angiogenesis in vitro. Current Biology, 8(9), 529-532.
144. Cheng, Z., Ou, L., Zhou, X., et al. (2008). Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Molecular Therapy, 16(3), 571-579.
145. Song, H., Kwon, K., Lim, S., et al. (2005). Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Molecules and Cells, 19(3), 402-407.
146. Li, H., Zuo, S., He, Z., et al. (2010). Paracrine factors released by GATA-4 overexpressed mesenchymal stem cells increase angiogenesis and cell survival. American Journal of Physiology-Heart and Circulatory Physiology, 299(6), H1772-H1781.
147. Fan, L., Lin, C., Zhuo, S., et al. (2009). Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. European Journal of Heart Failure, 11(11), 1023-1030.
148. Jo, J., Nagaya, N., Miyahara, Y., et al. (2007). Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: benefit of a novel nonviral vector, cationized dextran. Tissue Engineering, 13(2), 313-322.
149. Sun, L., Cui, M., Wang, Z., et al. (2007). Mesenchymal stem cells modified with angiopoietin-1 improve remodeling in a rat model of acute myocardial infarction. Biochemical and Biophysical Research Communications, 357(3), 779-784.
150. Huang, S. D., Lu, F. L., Xu, X. Y., et al. (2006). Transplantation of angiogenin-overexpressing mesenchymal stem cells synergistically augments cardiac function in a porcine model of chronic ischemia. The Journal of Thoracic and Cardiovascular Surgery, 132(6), 1329-1338.
151. Wang, M., Tan, J., Wang, Y., Meldrum, K. K., Dinarello, C. A., & Meldrum, D. R. (2009). IL-18 binding protein-expressing mesenchymal stem cells improve myocardial protection after ischemia or infarction. Proceedings of the National Academy of Sciences of the United States of America, 106(41), 17499-17504.
152. Li, Y., Hiroi, Y., Ngoy, S., et al. (2011). Notch1 in bone marrow-derived cells mediates cardiac repair after myocardial infarction. Circulation, 123(8), 866-876.
153. Lian, W. S., Cheng, W. T., Cheng, C. C., et al. (2011). In vivo therapy of myocardial infarction with mesenchymal stem cells modified with prostaglandin I synthase gene improves cardiac performance in mice. Life Sciences, 88(9-10), 455-464.
154. Bao, C., Guo, J., Lin, G., Hu, M., & Hu, Z. (2008). TNFR gene-modified mesenchymal stem cells attenuate inflammation and cardiac dysfunction following MI. Scandinavian Cardiovascular Journal, 42(1), 56-62.
155. Bao, C., Guo, J., Zheng, M., Chen, Y., Lin, G., & Hu, M. (2010). Enhancement of the survival of engrafted mesenchymal stem cells in the ischemic heart by TNFR gene transfection. Biochemical Cell Biology, 88(4), 629-634.